MPM, DCVC Bio back $53M round for a bold con­cept: Let pa­tients make their own CAR-T in vi­vo

The oner­ous process of mak­ing a per­son­al­ized CAR-T — one that in­volves ex­tract­ing cells from pa­tients, en­gi­neer­ing and then in­ject­ing them back — is one of the defin­ing fea­tures of the first gen­er­a­tion of en­gi­neered cell ther­a­pies. It’s part­ly why the treat­ments are so ex­pen­sive; it’s al­so an in­spi­ra­tion for new al­lo­gene­ic ap­proach­es that promise to be faster and cheap­er.

But a biotech start­up in Seat­tle wants to go fur­ther.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER